trending Market Intelligence /marketintelligence/en/news-insights/trending/dyIFzz8lsD0WkSSIVKIPvw2 content esgSubNav
In This List

Merrimack stockholders back oncology assets sale to Ipsen

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Merrimack stockholders back oncology assets sale to Ipsen

Merrimack Pharmaceuticals Inc.'s stockholders, at a March 30 special meeting, approved the sale of oncology assets to Ipsen SA.

The company will give Ipsen its commercialized pancreatic cancer product, Onivyde, including U.S. commercialization rights and its licensing agreements with Shire PLC.

In addition, the deal covers Merrimack's generic doxorubicin hydrochloride liposome injection, Doxil, which is advanced under a development, license and supply agreement with Actavis LLC.

Merrimack expects the transaction to be completed in the coming days.